Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968708 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,380
- Enrollment target
NCT00968708 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 5,380 participants.
The verdict
NCT00968708, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,380 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
Interventions
- DRUG Placebo
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,380 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968708
The ClinicalTrials.gov registry entry for NCT00968708 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00968708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968708 about?
NCT00968708 is a clinical study titled "Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome". The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
What is the current status of trial NCT00968708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,380 participants. The study started on 2009-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00968708?
The interventions under investigation include: Placebo (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00968708?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.